VUNO said it has achieved its highest annual revenue since its inception in 2014, thanks to a surge in revenue for VUNO Med-DeepCARS, its artificial intelligence (AI)-based cardiac arrest prediction solution, and increased sales in both domestic and international markets for its other AI medical ima
Government officials said they would authorize non-physicians, such as nurses and other professionals, to conduct cosmetic procedures like botulinum toxins (BTX) and fillers, citing the examples of North America and Europe.However, North Americans and Europeans inject BTX and fillers quite shallowly
In 2023, the life sciences sector, particularly Big Pharma, has witnessed a significant return to large-scale deal making.This resurgence is primarily driven by the looming patent cliff, with numerous key products facing the loss of patent protection within the next five years.The EY (Ernst & Young)
GI Cell, an affiliate of GI Innovation, has submitted an application to the Ministry of Food and Drug Safety for phase 1/2a clinical trials to evaluate the safety and efficacy of a combination therapy between GI Cell's allogeneic NK cell therapy, T.O.P. NK and GI-101A, in patients with recurrent and
Hanmi Pharm reported a groundbreaking performance for 2023, with consolidated sales and operating profit reaching 1.49 trillion won ($1.1 billion) and 220.7 billion won, up 11.97 percent and 39.5 percent from the previous year, thanks to royalties and strong domestic sales.The company also reported
LifeSemantics has completed a local proof of concept (PoC) for its new non-face-to-face healthcare platform, “Dr.Call Thai,” to enter the Thai market.The technology demonstration was conducted with Praram 9 Hospital, a tertiary general hospital in Bangkok, to review the service performance of Dr. Ca
LG Chem's life sciences business has hit a milestone by exceeding 1 trillion won ($755.8 million) in annual sales for the first time in the company's history. The performance was backed by strong sales from AVEO Oncology, a U.S. subsidiary acquired in April 2023. The sales represent a 30.1 percent g
Meta Fines, a drug repositioning company, said Thursday that it has signed a licensing-out agreement with BMI Korea for its cancer cachexia drug ASCA101_CC.Under the agreement, BMI Korea will co-own the global technology transfer rights of ASCA101_CC with Meta Fines and will have the right to licens
The government and the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses.The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenera
President Yoon Suk Yeol visited Seoul National University Bundang Hospital (SNUBH) to promote medical simulation training.President Yoon stressed the need to improve the quality of medical education and training, focusing on national university hospitals and strengthening regional essential medical
A research team at Gangnam Severance Hospital has uncovered a significant correlation between non-alcoholic fatty liver disease (NAFLD) and an increased risk of developing dementia in individuals over the age of 60.The study, led by Professors Lee Jung-il and Lee Hyun-woong of the Department of Gast
A bill has passed the National Assembly's plenary session, restricting medical residents from working more than 80 hours weekly.The new law will also prohibit doctor trainees from working more than 36 hours in a row and provide the basis for prioritizing the fostering of specialists in essential med
Enhertu (trastuzumab deruxtecan), a next-generation antibody-drug conjugate (ADC) developed by Daiichi Sankyo, recently passed the Pharmaceutical Reimbursement Evaluation Committee (PREC)'s deliberations, moving closer toward health insurance coverage.On Thursday, the Health Insurance Review and Ass
Sanofi Korea launched Aprovasc Tab, the first antihypertensive combination drug comprising irbesartan and amlodipine besylate co-developed with Handok on Thursday.Aprovasc won approval from the Ministry of Food and Drug Safety in November 2023 for treating essential hypertension in patients whose bl
Hanmi Pharma said it has signed a strategic agreement with its U.S. partner company, Assertio Holdings, which previously acquired Spectrum Pharmaceuticals, to re-acquire the rights to Rolontis, a long-acting neutropenia treatment and Korea's 33rd novel drug, for the Asian and African markets.Rolonti
Seoul National University Hospital (SNUH) said on Friday that YG Entertainment, a prominent K-pop entertainment agency, has contributed 100 million won ($75,358) to aid in the treatment and music rehabilitation of children with cochlear implants.The donation will be utilized to assist in covering su
Instead of surgery that requires drilling holes in the skull and inserting electrodes deep into the brain, researchers from the Institute for Basic Science (IBS) have announced a significant breakthrough in the treatment of Parkinson's disease.The team, led by Professors Cheon Jin-woo and Kwak Min-s
Takeda Korea said the National Health Insurance will reimburse its adult acquired hemophilia A (AHA) treatment Objzur Inj (susoctocog alpha) starting Thursday.Obizur is Korea's only blood clotting factor VIII treatment for adult AHA. It won the Ministry of Food and Drug Safety approval in March last
Osang Healthcare said it received approval from the Ministry of Food and Drug Safety for "GeneFinder HLA-B*58:01 Plus RealAmp Kit," designed to help better treat gout patients.The kit tests for the HLA-B5801 genetic variant, which is used to identify gout patients at risk of severe skin reactions to
BNC Korea said Thursday that it has signed a joint research and development agreement with SML Biopharm to develop a GLP1 agonist for treating diabetes and obesity using mRNA technology.Under the agreement, SML Biopharm will utilize its mRNA platform expression technology to express target genes in